Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALMB-0168 + PD-1 inhibitor
- Development stage
- Preclinical
- Lead developer
- AlaMab Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ALMB-0168 + PD-1 inhibitor is a preclinical combination therapy being developed by AlaMab Therapeutics for the treatment of solid tumors and bone-involved cancers. The combination consists of ALMB-0168, a first-in-class humanized monoclonal antibody that targets Connexin 43 (Cx43) hemichannels, and an unspecified PD-1 (programmed death-1) checkpoint inhibitor. ALMB-0168 acts as an agonist to activate Cx43 hemichannels, which triggers the release of ATP and other tumor-inhibiting factors into the tumor microenvironment. This mechanism is intended to work synergistically with the PD-1 inhibitor, which enhances T-cell mediated anti-tumor immunity. The program is currently in the IND-enabling or early clinical development stage for bone-involved cancers.
- Other names
- ALMB-0168 + PD-1 inhibitor0168 + PD1
02
Targets
GJA1 (Connexin43 Hemichannel)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ALMB-0168 + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALMB-0168 + PD-1 inhibitor.